[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-covid-condition\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-covid-condition":59},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,72,93,124,146,179,204],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100626451","long-term-health-effects-of-previous-coronavirus-disease-2019-covid-19-in-patients-undergoing-preoperative-anesthesia-evaluation-100626451",false,"NCT07435805","Long-Term Health Effects of Previous Coronavirus Disease 2019 (COVID-19) in Patients Undergoing Preoperative Anesthesia Evaluation","Long-Term Clinical and Health Effects of Previous Coronavirus Disease 2019 (COVID-19) in Patients Presenting for Preoperative Anesthesia Evaluation","Inclusion Criteria:\n\n* Age ≥18 years\n\nPresentation to the preoperative anesthesia clinic\n\nSelf-reported history of laboratory-confirmed COVID-19 infection\n\nAbility to provide informed consent\n\nWillingness to complete the post-COVID clinical questionnaire\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n\nNo history of COVID-19 infection\n\nRefusal to participate or incomplete questionnaire\n\nCognitive impairment or communication difficulties preventing reliable data collection","ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","OBSERVATIONAL","The Coronavirus Disease 2019 (COVID-19) pandemic has resulted in persistent health problems in a significant proportion of individuals after recovery from the acute infection. These long-term manifestations, commonly referred to as post-COVID-19 condition or long COVID, may involve respiratory, cardiovascular, neurological, psychological, and general health domains. Understanding these sequelae is particularly important in patients undergoing preoperative anesthesia evaluation, as residual symptoms may influence perioperative risk assessment and clinical decision-making. This cross-sectional observational study aims to evaluate the long-term clinical and health effects of previous COVID-19 infection in adult patients presenting to the preoperative anesthesia clinic. Patients aged 18 years and older who report a history of confirmed COVID-19 infection will be included. Clinical data related to the acute infection period (disease severity, hospitalization, intensive care unit (ICU) admission, oxygen therapy, and radiological findings) will be retrospectively obtained from hospital records. At the time of preoperative assessment, participants will complete a structured post-COVID-19 clinical questionnaire to evaluate persistent symptoms across multiple organ systems. The study seeks to determine the prevalence and characteristics of long-term post-COVID-19 symptoms and to explore potential associations between acute disease severity and ongoing health complaints. No additional medical intervention will be performed as part of this research.",[24,25,26],"Post-COVID Condition","Long COVID","Sequelae of COVID-19",[24,28,29,30],"Preoperative Assessment","Cross-Sectional Study","COVID-19 Sequelae","RECRUITING","2026-06-02",{"date":34,"type":35},"2026-06-04","ACTUAL",{"date":37,"type":35},"2025-12-01",{"date":39,"type":20},"2026-06-20",{"name":41,"class":42},"Elazıg Fethi Sekin Sehir Hastanesi","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100633751","supercap-program-to-improve-cognition-and-daily-functioning-in-post-covid-19-condition-100633751","NCT07530757","SuperCAP Program to Improve Cognition and Daily Functioning in Post-COVID-19 Condition","Randomized Controlled Trial to Assess the Efficacy of a Supervised Computerized Active Program (SuperCAP) to Improve Cognition and Daily Functioning in People With Post-COVID-19 Condition","Inclusion Criteria:\n\n* Diagnosis of PCC, defined as the presence of three or more symptoms associated with COVID-19 infection for at least three months, not explained by other diseases.\n* Age 18 to 65 years.\n* Willingness to participate in an app-based intervention program aimed at improving daily Functioning in People Living with PCC.\n* Evidence of patient-reported cognitive difficulties emerging after COVID-19, operationalized as a WHODAS 2.0 Cognition Domain (D1) score \\> 6 at baseline via RedCAP.\n* Digital proficiency defined as scoring ≥4 on MDPQ-16 item 2a (sending emails) and ≥3 on item 6a (using the device's app store) via RedCAP.\n* Self-reported ability to use a mobile application for approximately 15 minutes per day, 5 days per week, considering their current symptoms.\n* Possession of a personal smartphone compatible with the study mobile application (eSalut), with sufficient storage space and operating system version required for installation.\n\nExclusion Criteria:\n\n* Inability to undergo neuropsychological tests or additional assessments.\n* Prior use of the SuperCAP program.\n* Current participation in a trial or program aimed at improving PCC symptoms.\n* Any condition that, in the investigator's opinion, could make participation unsafe, complicate interpretation of study results, interfere with achievement of study objectives, or otherwise affect the participant's ability to complete the study.","65 Years",{"count":53,"type":20},100,"INTERVENTIONAL",[56],"NA","The goal of this study is to determine whether the SuperCAP intervention program is superior to control in reducing disability from baseline to the post-intervention assessment in people with Post-COVID-19 Condition.\n\nThe main question it aims to answer is whether participants assigned to SuperCAP experience a greater reduction in disability, defined as an improvement of at least 5 points on the WHODAS 2.0 from baseline to the post-intervention visit, compared with participants in the control group.\n\nParticipants assigned to the SuperCAP intervention will undergo a series of sessions that include psychoeducation, adaptive cognitive training exercises, fatigue self-management strategies, and multidisciplinary content.",[59],"Post COVID Condition",[59,25,61],"SuperCAP","NOT_YET_RECRUITING","2026-04-07",{"date":65,"type":35},"2026-04-15",{"date":67,"type":20},"2026-04",{"date":69,"type":20},"2027-04",{"name":71,"class":42},"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":80,"targetDuration":4,"studyType":54,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":91,"locationsCount":43},"100615853","phase-2-sonlicromanol-in-post-covid-100615853","NCT07298005","Sonlicromanol in Post-COVID","SON4PEM Study: Sonlicromanol in Post-COVID: A Randomized, Double-blind, Placebo-controlled, Phase II Trial","SON4PEM","Inclusion Criteria:\n\n* Post COVID according to WHO criteria and verified by post COVID physician\n* Post-exertional malaise (PEM) according to DSQ-PEM questionnaire\n* Bell's disability score 20-70%\n* Mild initial SARS-CoV-2 infection (no hospitalisation)\n* WHO performance score of 0 before initial SARS-CoV-2 infection\n\nExclusion Criteria:\n\n* Patients at risk for cardiac conduction disorders\n* History of clinical significant gastro-intestinal surgery or dysmotility that impairs the adsorption of the IMP\n* Clinically significant respiratory or cardiovascular disease\n* Unstable neurological disease\n* Clinically significant active psychiatric disorder that requires treatment\n* History of substance abuse\n* Active malignancy within the past 5 years\n* History of solid organ transplantation\n* Active HIV, hepatitis B or C infection\n* BMI \\\u003C 18.5 or \\> 35\n* Pregnancy or breastfeeding\n* Clinically relevant laboratory test value outside the reference range\n* Use of the following medication, unless stable for at least one month before study and remaining stable throughout the study: (multi)vitamins, co-enzyme Q10, Vitamin E, riboflavin, amino acids, antioxidant supplements and any medication negatively influencing mitochondrial functioning (including but not limited to valproic acid, glitazones, statins, antivirals, amiodarone and NSAIDs)\n* Use of the following medication: any moderate or strong Cytochrome P450 (CYP)3A4 inhibitors (all 'conazoles-anti-fungals', HIV antivirals, grapefruit), strong CYP3A4 inducers ((including HIV antivirals, carbamazepine, phenobarbital, phenytoin, rifampicin, St. John's wort, pioglitazone, troglitazone) or any medication metabolized by CYP3A4 with a narrow therapeutic index, medication known to be substrate of Organic Cation Transporter 1 (OCT1) and organic cation transporter 2 (OCT2) or strong P-glycoprotein inhibitors (including amiodarone, azithromycin, captopril, clarithromycin, cyclosporine, piperine, quercetin, quinidine, quinine, reserpine, ritonavir, tariquidar, and verapamil).\n* Use of any medication known to affect cardiac repolarization unless QTc interval at screening is normal during stable treatment for a period of two weeks, or 5 half-lives",{"count":81,"type":20},80,[83],"PHASE2","The aim of this randomized, double-blind, placebo-controlled, phase II trial, is to study the effect of sonlicromanol on fatigue in patients with post-COVID who experience post-exertional malaise (PEM).",[59],{"date":87,"type":35},"2026-04-13",{"date":67,"type":20},{"date":90,"type":20},"2027-03",{"name":92,"class":42},"Michele van Vugt",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":101,"conditions":102,"keywords":108,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":120,"locationsCount":123},"100618493","expanded-access-use-of-human-umbilical-cord-blood-regenecyte-infusion-in-patients-with-chronic-fatigue-of-post-covid-condition-100618493","NCT07332338","Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition","Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion for Patients With Post-COVID Condition","Inclusion Criteria:\n\n* Male or female aged ≥ 18\n* With post-COVID condition\n* Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR (polyermerase chain reaction) or antigen test)\n* Not eligible for participation in any ongoing clinical trials of post-COVID condition with REGENECYTE\n* Able to provide signed informed consent (by the subject or his\u002Fher legally authorized representative)\n* Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent\n\nExclusion Criteria:\n\n* Neurological disorders prior to COVID-19 diagnosis\n* With pre-existing terminal illness\n* With known immune disease\n* Is pregnant or breastfeeding\n* Is currently participating in another investigational study or has been taking any other investigational product (IP) within the last 4 weeks before screening\n* Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period\n* Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases\n* Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters","EXPANDED_ACCESS","REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.",[103,24,104,25,105,106,107],"Post-COVID-19 Condition","Post-COVID Syndrome","Chronic Fatigue","Chronic Fatigue Symptoms","Fatigue Post Viral",[25,109,110,111,112,113,114,115],"Post-COVID syndrome","Post-COVID condition","Umbilical cord blood","REGENECYTE","Post-COVID fatigue","Chronic fatigue symptoms","Fatigue post viral","AVAILABLE","2026-03-18",{"date":119,"type":35},"2026-03-23",{"name":121,"class":122},"StemCyte, Inc.","INDUSTRY",2,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":131,"targetDuration":4,"studyType":54,"phases":133,"briefSummary":135,"conditions":136,"keywords":137,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100607117","phase-3-a-study-of-human-umbilical-cord-blood-regenecyte-infusion-in-patients-with-post-covid-condition-100607117","NCT07184385","A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition","A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Phase III Study to Assess the Efficacy of Human Umbilical Cord Blood (REGENECYTE) Infusion in Reducing Fatigue in Post-COVID Condition","Inclusion Criteria:\n\n* Male or female aged ≥ 18\n* With post-COVID condition\n* Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR or antigen test)\n* Able to provide signed informed consent (by the subject or his\u002Fher legally authorized representative)\n* Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent\n\nExclusion Criteria:\n\n* Neurological disorders prior to COVID-19 diagnosis\n* With pre-existing terminal illness\n* With known immune disease\n* Is pregnant or breastfeeding\n* Is currently participating in another investigational study or has been taking any other investigational product within the last 4 weeks before screening\n* Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period\n* Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases\n* Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters",{"count":132,"type":20},60,[134],"PHASE3","REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.",[25,103,104,24],[110,109,25,112,113,111],"2025-09-18",{"date":140,"type":35},"2025-09-23",{"date":142,"type":20},"2026-03-31",{"date":144,"type":20},"2027-09-30",{"name":121,"class":122},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":54,"phases":156,"briefSummary":157,"conditions":158,"keywords":162,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":175,"leadSponsor":177,"locationsCount":43},"100594012","effects-of-hydrotherapy-during-post-covid-19-rehabilitation-100594012","NCT07013903","Effects of Hydrotherapy During Post-COVID-19 Rehabilitation","Effects of Kneipp Hydrotherapy During Inpatient Post-Covid-19 Rehabilitation: A Randomized Controlled Trial","HydroCoVital A","Inclusion Criteria:\n\n* Diagnosis of Post-COVID Syndrome (ICD-10 code: U08.9)\n* Barthel-Index \\>80\n* Referred to the reference center for Post-COVID rehabilitation\n* Owning a smartphone to receive digital questionnaires and to use the measurement app for heart rate variability\n* Written informed consent\n\nExclusion Criteria:\n\n* Existing contraindications for Kneipp hydrotherapy like severe cardiovascular diseases (e.g., decompensated heart failure, unstable angina pectoris, acute myocardial infarction), severe venous diseases (e.g., acute deep vein thrombosis of the leg), severe neurological diseases (e.g., uncontrolled epilepsy)\n* Prior regular practice of Kneipp applications",{"count":155,"type":20},50,[56],"This randomized controlled study evaluates the effects of cold water hydrotherapy as an adjunct to standard rehabilitation in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to standard rehabilitation alone.",[159,160,161,24],"Post-COVID \u002F Long-COVID","POST-Covid 19","Post COVID Syndrome",[163,164,165,25,166,167,168,169,110,170],"rehabilitation","therapy","Post-COVID","intervention","hydrotherapy","Kneipp","balneotherapy","quality of life","2025-08-21",{"date":173,"type":35},"2025-08-28",{"date":171,"type":35},{"date":176,"type":20},"2027-10-31",{"name":178,"class":42},"Schön Klinik Berchtesgadener Land",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":54,"phases":187,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":43},"100528085","pursuing-reduction-in-fatigue-after-covid-19-via-exercise-and-rehabilitation-prefacer-a-randomized-feasibility-trial-100528085","NCT06156176","Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial","PREFACER","Inclusion Criteria:\n\n* Adults of at least 18 years of age\n* Able to provide informed consent\n* Can speak and understand English\n* Documented history of SARS-CoV-2 infection (positive PCR\u002Fantigen test during acute illness or clinical diagnosis by physician during or after the acute illness)\n* Fatigue symptoms within 3 months of COVID-19 infection, lasting at least 2 months\n* Fatigue symptoms cannot be explained by an alternative diagnosis\n* Fatigue symptoms may be new onset following initial recovery from an acute COVID-19 infection or persist from the initial illness\n* Fatigue symptoms may have an episodic nature, fluctuate or relapse over time\n* Minimal functional capability: able to walk 10-15 minutes and be recovered within 30-60 minutes or without significant post-exertional malaise (PEM)\n* Has applicable technology to access Microsoft Teams and Webex (i.e., computer, laptop, tablet)\n\nExclusion Criteria:\n\n* Active SARS-CoV-2 infection\n* Pre-existing physical, cognitive, and\u002For mental health conditions that make exercise contraindicated, consent unattainable, or that cause symptoms similar to those seen in post COVID-19 (e.g., major neurocognitive disorder, schizophrenia, chronic fatigue syndrome) that could affect data\n* Inability to follow study procedures\n* Pregnant and\u002For breastfeeding\n* Received investigational agents as part of a separate study within 30 days of the screening visit\n* Has any type of metal bodily implant in head or heart (i.e., pins, plates, pacemakers)\n* Current participation in other studies related to COVID-19, exercise, and\u002For fatigue interventions OR participation within 30 days of the screening visit",{"count":132,"type":20},[56],"Long COVID is a complex condition that affects approximately 1.4 million Canadians following SARS-CoV-2 infection. Fatigue is the most common symptom of Long COVID. This feasibility trial will evaluate a new rehabilitation program called COVIDEx for treating fatigue after COVID-19, and compare its effectiveness to the standard treatment currently used. The experimental treatment group will receive an 8-week multi-modal rehabilitation program with two 50-minute sessions per week. 60 participants will be recruited, randomly assigned to the COVIDEx program or standard of care (SoC) and followed for 24 weeks.",[190,191,192,104,193,194,24],"Long-COVID","Long COVID-19","Post-COVID-19 Syndrome","Fatigue","Post COVID-19 Condition","2025-07-29",{"date":197,"type":35},"2025-08-01",{"date":199,"type":35},"2025-04-01",{"date":201,"type":20},"2026-04-01",{"name":203,"class":42},"Lawson Research Institute of St. Joseph's",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":212,"targetDuration":214,"studyType":21,"phases":4,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":43},"100488331","munich-long-covid-registry-for-children-adolescents-and-adults-100488331","NCT05638724","Munich Long COVID Registry for Children, Adolescents, and Adults","Munich Long COVID Registry for Children, Adolescents, and Adults (MLC-R)","MLC-R","Inclusion Criteria:\n\nI. Written informed consent of the patient or legal guardian.\n\nII. Confirmed SARS-CoV-2 vaccination and\u002For confirmed or probable SARS-CoV-2 infection: Positive SARS-CoV-2 polymerase chain reaction (PCR) or rapid antigen test (AST), documented probable COVID-19 (e.g., typical CT scan), probable COVID-19 with a history of high-risk contact, anti-SARS-CoV-2-N antibodies (and\u002For in non-vaccinated people -S-IgG antibodies) following probable COVID-19.\n\nIII. Additional ICD-10 codes: U09.9!V: Suspected post-COVID-19 condition, unspecified; U12.9!V: suspected adverse reactions to COVID-19 vaccine use, unspecified (post-COVIDvac condition).\n\nExclusion Criteria:\n\n* Any subsequent medical data that question the diagnosis of PCC or post-COVIDvac condition\n* Clinical picture can be explained by another underlying disease.\n* Pregnancy",{"count":213,"type":20},1000,"5 Years","The MLC-R aims to create a large-scale registry that provides data on epidemiology, phenotypes, and disease trajectories of and health care for Long COVID at any age in Germany, which can be used for future clinical trials.",[24],[25,165,218,219,220,221],"ME\u002FCFS","CFS\u002FME","SARS-CoV-2","COVID-19","2024-02-14",{"date":224,"type":35},"2024-02-15",{"date":226,"type":35},"2022-07-20",{"date":228,"type":20},"2027-07-20",{"name":230,"class":42},"Technical University of Munich"]